Activation of cannabinoid CB 1 and CB 2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 765-777

  Rahn, E J ^a   Makriyannis, A ^b   Hohmann, A G ^a  

^a University of Georgia ^*  (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Allodynia; Cancer; Cannabinoid; CB 1; CB 2; Chemotherapy; Hyperalgesia; Neuropathic pain

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MORPHINE; OPIATE AGONIST; RIMONABANT; SODIUM CHLORIDE; VINCRISTINE; BENZOXAZINE DERIVATIVE; BORNANE DERIVATIVE; CANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; ENANTIOMER; EVOKED RESPONSE; HYPERSENSITIVITY; MALE; MODULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD; SPINE; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; HINDLIMB; HYPERESTHESIA; INSTRUMENTATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; METHODOLOGY; NEURALGIA; PAIN ASSESSMENT; PAIN THRESHOLD; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STIMULATION; TEMPERATURE SENSE;

ANIMALS; BENZOXAZINES; BODY WEIGHT; BORNANES; CANNABINOIDS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB; HYPERESTHESIA; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SPINAL; MALE; MORPHINE; MORPHOLINES; NAPHTHALENES; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TEMPERATURE SENSE; VINCRISTINE;

EID: 35748970190     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707333     Document Type: Article

References (69)

1. Aley KO, Levine JD (2002). Different peripheral mechanisms mediate enhanced nociception in metabolic/toxic and traumatic painful peripheral neuropathies in the rat. Neuroscience 111: 389-397.
2. Authier N, Coudore F, Eschalier A, Fialip J (1999). Pain related behaviour during vincristine-induced neuropathy in rats. Neuroreport 10: 965-968.
3. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2003a). An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 182: 12-20.
4. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2000). Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 887: 239-249.
5. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2003b). A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 24: 797-805.
6. Bacon M, James K, Zee B (2003). A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer 13: 428-434.
7. 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 1530-1538.
8. Bridges D, Ahmad K, Rice AS (2001). The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133: 586-594.
9. 2 receptor. Eur J Pharmacol 396: 141-149.
10. Cata JP, Weng HR, Chen JH, Dougherty PM (2006a). Altered discharges of spinal wide dynamic range neurons and downregulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 138: 329-338.
11. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM (2006b). Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72: 151-169.
12. Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V (2000). Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12: 2079-2086.
13. Flatters SJ, Bennett GJ (2004). Ethosuximide reverses paclitaxel and vincristine-induced painful peripheral neuropathy. Pain 109: 150-161.
14. Flatters SJ, Bennett GJ (2006). Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122: 245-257.
15. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
16. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
17. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
18. Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997). The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221: 157-160.
19. Hohmann AG (2005). A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain 118: 3-5.
20. Hohmann AG, Briley EM, Herkenham M (1999). Pre and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 822: 17-25.
21. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
22. Hohmann AG, Herkenham M (1998a). Regulation of cannabinoid and mu opioid receptor binding sites following neonatal capsaicin treatment. Neurosci Lett 252: 13-16.
23. Hohmann AG, Tsou K, Walker JM (1998b). Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett 257: 119-122.
24. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
25. 2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42.
26. Jackson DV, Wells HB, Atkins JN, Zekan PJ, White DR, Richards II F et al. (1988). Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 84: 1016-1022.
27. Joshi SK, Hernandez G, Mikusa JP, Zhu CZ, Zhong C, Salyers A et al. (2006). Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience 143: 587-596.
28. Kamei J, Tamura N, Saitoh A (2005). Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain 117: 112-120.
29. 2+ concentration in the spinal dorsal horn in an animal model of neuropathic pain. Pain 68: 85-96.
30. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL et al. (2003). A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103: 175-186.
31. LaBuda CJ, Little PJ (2005). Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods 144: 175-181.
32. Lynch III JJ, Wade CL, Zhong CM, Mikusa JP, Honore P (2004). Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 110: 56-63.
33. Mackie K, Hille B (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89: 3825-3829.
34. Mackie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15: 6552-6561.
35. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
36. Mao J, Price DD, Lu J, Keniston L, Mayer DJ (2000). Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett 280: 13-16.
37. Mao J, Price DD, Mayer DJ (1995). Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61: 353-364.
38. Martin WJ, Hohmann AG, Walker JM (1996). Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 16: 6601-6611.
39. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
40. 2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757.
41. 2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92: 3562-3574.
42. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL (2001). Vincristine-induced allodynia in the rat. Pain 93: 69-76.
43. Ossipov MH, Zhang ET, Carvajal C, Gardell L, Quirion R, Dumont Y et al. (2002). Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y. J Neurosci 22: 9858-9867.
44. Ozcay F, Kayiran SM, Ozbek N (2003). Successful medical management of neutropenic enterocolitis (typhlitis) in a child with acute lymphoblastic leukemia. Turk J Pediatr 45: 248-250.
45. Pascual D, Goicoechea C, Suardiaz M, Martin MI (2005). A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118: 23-34.
46. Pertwee RG, Ross TM (1991). Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9- tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 30: 67-71.
47. Polomano RC, Bennett GJ (2001a). Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2: 8-14.
48. Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001b). A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94: 293-304.
49. Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan Jr TP, Ossipov MH et al. (2001). Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J Neurosci 21: 5281-5288.
50. 2 cannabinoid receptors. Anesthesiology 99: 955-960.
51. 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22: 371-379.
52. Sandler SG, Tobin W, Henderson ES (1969). Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 19: 367-374.
53. Siau C, Bennett GJ (2006). Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 102: 1485-1490.
54. Strangman NM, Walker JM (1999). The cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophys 81: 472-477.
55. Taddese A, Nah SY, McCleskey EW (1995). Selective opioid inhibition of small nociceptive neurons. Science 270: 1366-1369.
56. Tanner KD, Levine JD, Topp KS (1998). Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 395: 481-492.
57. Tolstoi LG (2002). Drug-induced gastrointestinal disorders. Medscape Pharmacother 4, no. 437034.
58. Topp KS, Tanner KD, Levine JD (2000). Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 424: 563-576.
59. Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I (2004). The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci lett 371: 167-170.
60. 2 receptors. Science 310: 329-332.
61. Vera-Portocarrero LP, Zhang ET, Ossipov MH, Xie JY, King T, Lai J et al. (2006). Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience 140: 1311-1320.
62. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2005). Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132: 1093-1102.
63. Weng HR, Cordella JV, Dougherty PM (2003). Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103: 131-138.
64. 2 receptor agonists. Curr Med Chem 14: 917-936.
65. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
66. Yaksh TL, Rudy TA (1976). Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17: 1031-1036.
67. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 2750-2754.
68. 1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785.
69. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.